Although excessive immune stimulation was observed during cancer immunotherapy in an early clinical trial for the CD137 monoclonal antibody (mAb) urelumab, a low dose of urelumab is relatively safe (15, 16). This evidence concerns the gene TNFRSF9 and cancer.